

MEDICAMEN Biotech Limited



Regd. Office :
10, Community Centre No. 2,
Ashok Vihar, Phase-II,
Delhi-110052
CIN No. L74899DL1993PLC05694

Tel. : 27463506, 47589500
Toll Free No. : 1800 3000 7889,
1800 1029 010
Fax : 011-27138171
Web : www.medicamen.com

Provisional Financial Results for the quarter ended 30th June 2014				
PART I				
Particulars	(Rs. In Lacs)			
	3 Months Ended 30/06/2014	Preceding 3 Months Ended 31/03/2014	Corresponding 3 Months Ended 30/06/2013	Year Ended 31/03/2014
	Unaudited	Audited	Unaudited	Audited
01. Income from operations				
(a) Net Sales/Income from operations (Net of excise duty)	1902.24	2239.17	1846.46	7324.86
(b) Other Operating Income	0.00	0.00	0.00	0.00
(c) Total Income from Operations (Net)	1902.24	2239.17	1846.46	7324.86
02. Expenses				
a) Cost of Material Consumed	1171.99	1549.64	1011.77	4444.06
b) Cost of Goods Traded	80.76	102.45	15.59	349.96
c) Changes in inventory of Finished Goods and Work in Progress	34.57	(43.99)	204.26	148.89
d) Employees Benefits Expenses	155.95	138.15	145.46	557.56
e) Depreciation and Amortisation Expenses	51.88	39.90	40.06	160.94
f) Other expenses	372.29	464.12	344.95	1416.61
TOTAL EXPENSES	1867.45	2250.26	1762.10	7078.00
03. Profit/(Loss) from Operations before other Income, Finance Cost and Exceptional Items (1-2)	34.80	(11.10)	84.36	246.86
04. Other Income	44.63	39.00	23.51	60.62
05. Profit/(Loss) from ordinary activities before Finance Cost and Exceptional Items (3+4)	79.43	27.91	107.87	307.48
06. Finance Cost	63.09	77.51	62.16	289.61
07. Profit/(Loss) from Ordinary Activities after Finance Cost but before Exceptional Items (5-6)	16.34	(49.61)	45.71	17.87
08. Exceptional Items	0.00	0.00	0.00	0.00
09. Profit /Loss from Ordinary Activities before tax (7+8)	16.34	(49.61)	45.71	17.87
10. Tax Expenses				
Current Year	3.11	(9.45)	0.00	3.41
Tax Related to Earlier Year	0.00	0.00	0.00	0.00
Deferred Tax Liability	(17.12)	4.22	0.24	5.05
11. Net Profit /Loss from Ordinary Activities After Tax (9-10)	30.35	(44.38)	45.47	9.42
12. Extraordinary Items (Net of Tax expenses)	-	-	-	-
13. Net Profit/Loss for the period (11-12)	30.35	(44.38)	45.47	9.42
14. Paid-up equity share capital (Rs. 10/- per share)	891.36	891.36	849.00	891.36
15. Reserve excluding revaluation reserves				736.40

For Medicamen Biotech Ltd.


(B.K. Gupta)
Managing Director

Works : SP-1192 A & B, PHASE-IV, INDUSTRIAL AREA, BHIWADI-301019 DISTT. ALWAR, BHIWADI (RAJASTHAN)
Phones : 01493-221291, 221292 Fax : 01493-221948
PLOT Nos. 86/87, SECTOR-6A, INDUSTRIAL AREA, BHEL, RANIPUR, HARIDWAR, UTTARAKHAND
Ph : 01334-239488, 239489 Fax : 01334-239490

16. Earning Per Share before & after extraordinary items (Rs.) (not annualised)				
Basic	0.34	(0.52)	0.54	0.11
Diluted	0.34	(0.52)	0.54	0.11

PART II				
Select Information for the Quarter ended 30/06/2014				
A PARTICULARS OF SHAREHOLDING				
1 Public Shareholding				
- No. of Shares	5143518	5143518	5174591	5143518
- Percentage of Shareholding	57.70	57.70	60.95	57.70
2 Promoters and Promoter Group Shareholding				
a) Pledged /Encumbered				
- Number of Shares	1861200	1861200	1861200	1861200
- Percentage of Shares (as a % of the total shareholding of promoter and promoter group)	49.37	49.37	56.14	49.37
- Percentage of Shares (as a % of the total share capital of the company)	20.88	20.88	21.92	20.88
b) Non-Encumbered				
- Number of Shares	1908888	1908888	1454209	1908888
- Percentage of Shares (as a % of the total shareholding of promoter and promoter group)	50.63	50.63	43.86	50.63
- Percentage of Shares (as a % of the total share capital of the company)	21.42	21.42	17.13	21.42

Particulars	3 Months ended 30/06/2014
B INVESTOR COMPLAINTS	
Pending at the beginning of the quarter	NIL
Received during the quarter	1
Disposed of during the quarter	1
Remaining unresolved at the end of the quarter	NIL

NOTES :

1. The above results after being reviewed by the Audit Committee have been taken on record by the Board at its Meeting held on 14th, August, 2014.
2. The figures are regrouped in previous year also, wherever considered necessary.
3. The company operates in singal segment , viz. Pharmaceutical Formulations.
4. Limited Review as required under Clause 41 of the Listing Agreement has been carried out by the Statutory Auditors.
5. Depreciation for the period April to June, 2014, has been calculated as per the provisions of the Companies Act, 2013. In addition to depreciation charged for the current period, an amount of Rs.47.39 Lacs has been charged to the opening reserves, for assets whose useful life is NIL.

Place : Delhi
Dated : 14.08.2014

For & on behalf
Medicamen Biotech Limited


(B.K. Gupta)
Managing Director